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Abstract
Background: There are still numerous protein subfamilies within families and superfamilies that do not yet have
conclusive empirical experimental evidence providing a specific function. These proteins persist in databases with
the annotation of a specific ‘putative’ function made by association with discernible features in the protein
sequence.
Results: Here, we report the characterization of one such protein produced by the pathogenic soil bacterium
Burkholderia pseudomallei, BPSL1375, which provided evidence for putative hemolysins in the COG3176 family to
have experimentally validated hemolytic activity. BPSL1375 can be classified into the N-acyltransferase superfamily,
specifically to members of the COG3176 family. Sequence alignments identified seven highly conserved residues
(Arg54, Phe58, Asp75, Asp78, Arg99, Glu132 and Arg135), of which several have been implicated with N-
acyltransferase activity in previously characterized examples. Using the 3D model of an N-acyltransferase example as
a reference, an acyl homoserine lactone synthase, we generated 3D structure models for mutants of six of the
seven N-acyltransferase conserved residues (R54, D75, D78, R99, E132 and R135). Both the R99 and R135 mutants
resulted in a loss of hemolytic activity while mutations at the other five positions resulted in either reduction or
increment in hemolytic activity.
Conclusions: The implication of residues previously characterized to be important for N-acyltransferase activity to
hemolytic activity for the COG3176 family members of the N-acyltransferase provides validation of the correct
placement of the hemolytic capability annotation within the N-acyltransferase superfamily.
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Background
Burkholderia pseudomallei is a soil bacterium that
causes melioidosis, a deadly disease endemic to South
East Asia and Northern Australia [1]. This bacterium is
recognized as a potential category B biothreat agent due
to its aerosol infectivity and severe course of infection
[2]. Pathogenesis of B. pseudomallei remains poorly
understood despite a number of previous studies having
described the expression of several virulence factors,
particularly extracellular products with proteolytic, lipo-
lytic and hemolytic activity [3, 4], the Type VI secretion
system [5] and the capsule [6]. A toxin that deamidates
and subsequently inactivates helicase activity of the
translation initiation factor (eIF4a) has been reported
[7]. Other aspects of this bacterium’s genome has also
been explored including the existence of small RNAs [8]
and methylation of genomic DNA by restriction modifi-
cation systems [9]. Nevertheless, much of the genome
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remains annotated as genes encoding hypothetical
proteins.
Most bacterial pathogens have the capacity to acquire
nutrients and minerals from the infected hosts [10]. Free
iron may generate damaging free radicals and therefore
is typically maintained at low concentrations within the
host. Bacterial pathogens are known to secrete extracel-
lular proteins that lyse erythrocytes in order to acquire
the free iron released from heme [11]. Hemolysins, one
such class of secreted proteins, are exotoxins that have
lytic activity against erythrocytes and are often impli-
cated as virulence factors. These proteins also allow bac-
teria to evade the immune system by escaping from
phagosomes [12]. Many hemolysins act by forming pores
on the target cell’s membrane while others act through
surfactant-like or enzymatic mechanisms [13].
Hemolysins have been implicated in a variety of com-
plications arising from bacterial infections, ranging from
intestinal tract disease to septicemia. Hemolysins pro-
duced by Escherichia coli have been associated with
enterotoxicity and septicemia [14], whilst those secreted
by Vibrio vulnificus [15], Aeromonas hydrophila [16] and
Yersinia ruckeri [17] have been detected in high concen-
trations during fatal infections. Radke et al. [18] reported
that Listeria monocytogenes listeriolysin disrupts lyso-
somal and phagosomal membranes to allow for bacterial
escape into the host cytoplasm to initiate bacterial repli-
cation. Hemolysins have also been previously reported
for members of the B. cepacia complex [19, 20] and it is
known that different strains produced different hemoly-
sins with differing functions. The Japanese clinical strain
had been reported to produce a hemolysin called cepaly-
sin that is capable of forming pores up to 30 nm in
diameter [21]. Two separate hemolysins have been de-
scribed for U.S clinical isolates with a size of 72 kDa and
22 kDa [22]. The hemolysins of British isolates are cap-
able of inducing apoptosis and degranulation of mam-
malian phagocytes [19] and thus quite distinct from
both the Japanese and the U.S strains due to its lack of
pore forming capacity.
A number of studies have reported the expression of
several B. pseudomallei heat-stable and heat-labile toxins
that exhibited cytolytic and hemolytic activity [23–25].
Elevated levels of either cytotoxicity or hemolytic activity
have also been detected in supernatant extracts of sta-
tionary growth phase cultures [24]. However, it is still
unclear if this hemolytic phenotype is the result of a sin-
gle enzyme or a result of the combined outcomes from
the reactions of different proteins.
Open reading frames (ORFs) annotated as hypothetical
proteins make up almost 25 % of the B. pseudomallei
genome [26]. Cruz-Migoni et al. [7] reported a genome-
wide project to characterize B. pseudomallei hypothetical
proteins in an attempt to discover proteins with novel
functions, which may include putative virulence factors.
In this paper, we report the characterization of the
protein encoded by the coding region bpsl1375 and pro-
vide definitive evidence of its ability to lyse erythrocytes.
In silico analysis revealed sequence level similarities to
members of the N-acyltransferase superfamily (Conserved
Domains Database ID: cl00357) from the COG3176 group
of the Clusters of Orthologous Groups (COGs) database.
Members of COG3176 have previously been annotated as
putative hemolysins.
Results
BPSL1375 is a member of the N-acyltransferase
superfamily
A systematic approach to characterize the functions of
coding regions annotated as hypothetical proteins by
Holden et al. [27] resulted in the extraction of all such
sequences followed by resubmission for sequence align-
ment based analysis. This included targeted searches for
previously reported virulence and pathogenicity factors
such as various hemolysins from other Gram negative
bacteria. One of these searches identified motifs previ-
ously observed in the hemolysin of Ralstonia eutropha
within the coding region of an ORF originally annotated
as encoding the hypothetical protein BPSL1375 by
Holden et al. [27]. A database search of the BPSL1375
sequence in GenBank revealed that the sequence con-
tained domains that could be remotely associated with
the N-acyltransferase (NAT) superfamily and shared se-
quence similarity to other proteins that were also anno-
tated as hypothetical proteins. The NAT superfamily
(Conserved Domains Database ID: cl00357) consists of
various enzymes that characteristically catalyze the
transfer of an acyl group onto its substrate. Among the
known members of this superfamily are proteins that
have been annotated as putative hemolysins (COG3176).
The PATRIC database’s [28] entry for BPSL1375 has
been updated to take into account this known homology
to hemolysin and thus carries a revised annotation for
BPSL1375 as ‘putative hemolysin’.
This homology to the NAT superfamily enabled us to re-
fine our BLASTP database searches using the higher quality
curated datasets in SWISSPROT/UniProt [29] and the Pro-
tein Data Bank (PDB) [30]. The UniProt search yielded 13
hits, all with scores lower than 40, E values of 0.07 or higher
and sequence identities of 25 % and lower. Two of the hits
were for acyl-homoserine-lactone (AHL) synthase, a well
characterized member of the NAT superfamily. The
BLASTP search against the PDB also yielded hits with
scores lower than 30, E values of 1.7 or higher and se-
quence identities of 37 % or lower. Again, we were able to
observe a hit for an acyl-homoserine-lactone synthase, spe-
cifically, the sequence for the crystal structure of Pseudo-
monas aeruginosa LasI [31] with the PDB code 1RO5.
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To identify highly conserved regions such as residues
that may be potential active sites or binding motifs, we
carried out multiple sequence alignment of the BPSL1375
sequence against 26 other sequences from the COG3176
family and representatives from the lysophospholipid
acyltransferase (LPLAT) family to which AHL synthase
belongs. From the alignments, we identified 7 residue po-
sitions – Arginine 54 (R54), Phenylalanine 58 (F58),
Aspartic Acid 75 (D75), Aspartic Acid 78 (D78), Arginine
99 (R99), Glutamic Acid 132 (E132) and Arginine 135
(R135) that were conserved in all 27 sequences (Fig. 1a).
The equivalent residue numbers for the LasI sequence are
provided in Fig. 1b. Six of these residues (R54, D75, D78,
R99, E132 and R135) carried charged side chains while
F58 is a hydrophobic amino acid.
BPSL1375 and its orthologs are conserved in Burkholderia
spp.
We then investigated whether BPSL1375 is common to
all Burkholderia spp. and twelve orthologs were discov-
ered in other Burkholderia species with available genome
sequences. These Burkholderia spp. orthologs were mainly
annotated as either hemolysin-like proteins or ornithine-
acyl N-acyltransferases. We further explored this conser-
vation by analyzing the presence and arrangement of the
bpsl1375 orthologs and the flanking coding regions in the
other Burkholderia species. We were able to match twelve
orthologous sequence regions within the Burkholderia
genus although seven of these appear to have possibly
undergone various levels of rearrangement (Fig. 2).
Scanning electron microscopy reveals evidence of
hemolysis by BPSL1375
The potential for BPSL1375 to have hemolytic activity as
suggested by the sequence alignment was investigated by
incubating purified recombinant BPSL1375 (Additional
file 1) with sheep erythrocytes. The expression and puri-
fication of recombinant BPSL1375 is discussed in more
detail below. Scanning electron microscopy (Fig. 3)
revealed that sheep erythrocytes treated with the recom-
binant BPSL1375 displayed crenated shapes with cyto-
plasmic blebbing on the membrane (Fig. 3b) compared
Fig. 1 Multiple sequence alignment of BPSL1375 and corresponding residue numbers of BPSL135 and LasI/1ro5. Multiple sequence alignment
has been done to identify highly conserved regions such as residues that may be potential active sites or binding motifs of BPSL1375 sequence
against 26 other sequences from the COG3176 family and representatives from the lysophospholipid acyltransferase (LPLAT) family to which AHL
synthase belongs. a Multiple sequence alignment of BPSL1375 with representatives of the COG3176 family and representatives of the LPLAT
family including the LasI sequence (PDB crystallographic structure 1ro5) – each sequence is labeled as either Genus.species_Protein
Name_Accesion number for Uniprot sourced data or Genus.species_Accession_number for GenBank sourced data; b Corresponding residue
numbers in BPSL1375 and P. aeruginosa LasI/1ro5 for the seven residues conserved throughout the alignment
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to untreated erythrocytes that presented the usual bicon-
cave discs appearance (Fig. 3a), nevertheless, blebbing
was not as notable as the positive control for lysis
(Fig. 3c). Recombinant E. coli carrying the bpsl1375 gene
(see below) that were grown on blood agar plates also
showed clear hemolytic zones (Fig. 3d). Confirmation of
BPSL1375 hemolytic activity then led us to perform
modeling and generation of recombinant mutants to en-
able the determination of key residue(s) required for
hemolytic activity.
Modeling and structural analysis
The importance of the seven conserved residues identi-
fied by multiple sequence alignment of BPSL1375 with
other available AHL synthases was initially investigated
using the crystal structure of P. aeruginosa LasI (PDB:
1RO5) as reference. The corresponding conserved resi-
dues of BPSL1375 in LasI are R54/R23, F58/F27, D75/
D44, D78/D47, R99/R70, E132/E101 and R135/R104
(Fig. 1b). The structural study of 1RO5 indicated that
these residues were involved in the formation of the sub-
strate binding pocket in an electrostatic cluster of the
molecule [31], thus suggesting that these residues play
key roles in supporting the proper structure and forma-
tion of the binding site.
Each of the seven conserved residues was substituted
in silico with residues from the same group of amino
acids such as R with K and D with E in order to main-
tain the protein’s general fold as well as the local confor-
mations at the substitution sites [32]. Visual analysis
using Chimera molecular graphics [33] revealed the
consistency of the local conformation for the substituted
residues compared to the original residues indicating the
suitability of the substitution in conserving the position
and orientation of the original residue in 3D space
(Fig. 4). We further investigated changes in the number
of hydrogen bonds with the neighboring residues that
resulted from the substitution. The substitution of R23K
reduced the number of hydrogen bonds formed from 5
to 4 (Fig. 4a), D44E from 4 bonds to 3 (Fig. 4b), D47E
from 4 bonds to 2 bonds (Fig. 4c), R70K from 5 bonds
to 3 (Fig. 4d), E101D from 6 bonds to 5 bonds (Fig. 4e)
and R104K with 5 bonds reduced to 3 bonds (Fig. 4f ).
With these mutant models as a guide, we expect the
changes in the number of hydrogen bonds to change the
interactions between the residues involved, thus, possibly
affecting the overall catalytic properties of the molecule.
In the next section, we demonstrate the effect of each
substitution on the hemolytic activity of BPSL1375.
Characterization of BPSL1375 and site directed mutants
In order to characterize the BPSL1375 protein, the
bpsl1375 gene was cloned from a clinical isolate
(B. pseudomallei D286) available in our laboratory.
Fig. 2 Conservation of bpsl1375 and neighboring genes in other members of the Burkholderia genus. The conservation of bpsl1375 matched
twelve orthologous sequence regions within the Burkholderia genus although seven of these appear to have possibly undergone various levels
of rearrangement. Bp: B. pseudomallei; Ba: B. ambifaria; Bc: B. cenopacia; Bt: B. thailandensis; Bm: B. mallei; B. multi ATCC: B. multivorans ATCC17616;
Bphy: B. phymatum; Bx: B. xenovorans
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The primers used for the work reported here (Table 1)
were designed using the available B. pseudomallei K96243
genome sequence. The amplified 819 bp ORF of bpsl1375,
encoding 272 amino acids, was successfully ligated into
the expression vector pET200/D-TOPO. The 37 kDa
BPSL1375 protein was expressed by E. coli BL21 (DE3)
and purified by affinity chromatography.
The E. coli clones expressing recombinant BPSL1375
produced clear hemolytic zones around the colonies on
trypticase soy agar containing 5 % sheep’s blood (Fig. 3d).
Quantification of BPSL1375 hemolytic activity on 3 %
sheep blood suspension for 1 h at 37 °C revealed up to
26.9 % hemolysis. To investigate the contribution of the
conserved amino acids towards the observed BPSL1375
hemolytic activity, site directed mutagenesis was per-
formed on R54, F58, D75, D78, R99, E132 and R135. Of
the seven conserved positions, six residues were success-
fully substituted: R54K, D75E, D78E, R99K, E132D and
R135K. All six successful site directed substitutions were
then confirmed by Sanger sequencing.
The R135K and R99K substitutions resulted in a
complete loss of hemolytic activity indicating that these
residues may be critical for the hemolytic activity observed
for BPSL1375 (Table 2). The other three substitutions of
E132D, D75E and R54K resulted in a non-significant
decrease of hemolytic activity. The hemolysis activity of
E132D was recorded at 22 % whereas D75E and R54K
hemolysis were at 18 % and 14 % respectively. This im-
plied that although these residues are conserved within
the COG3176 family members and most likely important
for BPSL1375 hemolytic activity, they may not be directly
involved in the catalytic reaction or interactions associated
with hemolysis and perhaps, have substrate binding roles
associated to substrate specificity determination. We also
noted that the hemolytic activity of the D78E mutant
increased up to 2.3 fold higher than the wild-type
(Table 2). For the work reported here, a single sampling to
quantify hemolysis by BPSL1375 was conducted at 1 h.
Future studies should investigate the hemolytic activity of
BPSL1375 and the site directed mutants over time.
Fig. 3 A comparison between the electron micrographs of cytoplasmic blebbing on the membrane and recombinant E. coli carrying the
bpsl1375 gene grown on blood agar plates. Scanning electron microscopy revealed that sheep erythrocytes treated with the recombinant
BPSL1375 displayed crenated shapes with cytoplasmic blebbing on the membrane (a) compared to untreated erythrocytes that presented the
usual biconcave discs appearance (b), nevertheless, blebbing was not as notable as the positive control for lysis (c). Recombinant E. coli carrying
the bpsl1375 gene (see below) that were grown on blood agar plates also showed clear hemolytic zones (d). a Normal biconcave disc shape of
untreated erythrocytes in PBS; b BPSL1375 treated erythrocytes showing the presence of discrete blebs (yellow arrow) on the erythrocyte; and c
erythrocytes in sterile distilled water that also show the blebs (yellow arrow) as a positive control for lysis. d Recombinant E. coli bpsl1375colonies
grown on trypticase soy agar with 5 % sheep blood after 24, 48 and 72 h of incubation at 37 °C showing clear hemolytic zones
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Fig. 4 Models of the amino acid substitutions generated using Chimera. Substitutions of the different residues also resulted in changes in the
number of hydrogen bonds with the neighboring residues. a R23K, b D44E, c D47E, d R70K, e E101D and f R104K
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Hemolysis induced by BPSL1375 wild type and mutant
proteins are temperature dependent
The BPSL1375 recombinant wild type and mutant pro-
teins were incubated individually in erythrocyte suspen-
sions to observe hemolysis at four different temperatures;
4 °C, 20°, 37 °C and 60 °C (Fig. 5a). Incubation was fixed
at 60 min for all reactions except for the 60 °C sample
which was limited to 15 min. The mixtures were centri-
fuged and the level of hemoglobin released was measured
at 545 nm. Poor hemolysis was observed for all samples at
4 °C, including the positive control B. pseudomallei lysate.
However, hemolysis at 20 °C was the highest for B. pseu-
domallei lysate, BPSL1375, BPSL1375/D78E, BPSL1375/
R99K and BPSL1375/R135K (Fig. 5a) whilst the highest
hemolysis at 37 °C was noted for BPSL1375/E132D. Incu-
bation at 60 °C abolished the activity of all samples except
for B. pseudomallei lysate. The presence of a heat labile
hemolysin has been reported for B. pseudomallei although
it has not been specifically identified [23]. Our results
suggest that BPSL1375 as wellas the mutants are heat-
labile, and BPSL1375 may therefore be the previously
uncharacterized heat labile hemolysin of B. pseudomallei
first reported by Ashdown and Koehler [23].
BPSL1375 is inhibited by high erythrocyte concentrations
The amount of hemolysin needed to lyse a single erythro-
cyte molecule was determined by incubating a fixed quan-
tity of B. pseudomallei lysate, BPSL1375 and the mutant
proteins with different concentrations (0.2 to 2.5 %) of
erythrocytes. According to Oberley et al. [34], one mol-
ecule of hemolytic protein is sufficient for lysis and there-
fore the amount of hemoglobin released by a constant
amount of protein is proportional to the erythrocyte con-
centration until a plateau is reached. Therefore, if more
than one molecule of protein is required for lysis, the
amount of hemoglobin released should increase to a peak
and then decrease. After 1 h at 37 °C, the mixtures were
centrifuged and the amount of hemoglobin released into
the supernatant was read at 545 nm. The B. pseudomallei
lysate lysed erythrocytes at all concentrations of sheep
blood while for BPSL1375 and its mutants, the percentage
of hemolysis decreased as erythrocyte concentrations in-
creased (Fig. 5b).
These results suggest that BPSL1375 employs a multi-
hit hemolytic mechanism that is similar to the hemolysins
of other pathogenic bacteria such as B. cereus [35],
Gardenella vaginalis [36], Streptococcus suis and Syne-
choctus sp. [37]. This mechanism is explained by the abil-
ity of a single toxin to bind only to a limited quantity of
cells to induce hemolysis and is inhibited in the presence
of a high ratio of erythrocytes to toxin molecule [38].
Therefore, keeping the hemolysin concentration constant
and increasing the number of erythrocytes suggests that
the optimal ratio is not achieved due to the presence of
excess erythrocytes. For instance, Inoue et al. [38] de-
scribed that two to five molecules of streptolysin O and
Clostridium perfringens delta toxin are required per
erythrocyte to induce hemolysis. This characteristic was
maintained in BPSL1375 and all of the mutants where
similar reduction in hemolytic activity was observed at
higher erythrocyte concentrations.
Discussion
Our characterization of the B. pseudomallei protein
BPSL1375 that was originally annotated as a hypothet-
ical protein by Holden et al. [27] but subsequently
revised to ‘putative hemolysin’ in the PATRIC database,
has enabled this protein to be classified as a member of
the N-acyltransferase (NAT) superfamily that includes
several putative hemolysins, other hypothetical proteins
Table 1 Primers used for PCR amplification of bpsl1375 and site
directed mutagenesis of bpsl1375















Table 2 Quantitation of hemolytic activity of the recombinant
wild type and mutant BPSL1375 proteins
Protein / Control Hemolysis
Activity (%)a
Distilled water 100
B. pseudomallei D286 lysate 80








aIncubation with erythrocytes for 60 min at 37 °C
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and AHL synthases - namely LasI of Pseudomonas
aeruginosa. The BPSL1375 sequence can be further
grouped into the COG3176 cluster with members that
contain hemolysin-like domains. This hemolytic po-
tential was validated by hemolysis assays and site di-
rected mutants. The hemolytic activity demonstrated
by the expression of BPSL1375 (Fig. 3d) is evidence
that the protein is the actual structural hemolysin and
that BPSL1375 is not merely a regulator of hemolytic
activity. To our knowledge, this is the first member
of the NAT superfamily with experimental evidence of
hemolytic activity.
Multiple sequence analysis to discover BPSL1375
amino acids that were shared with its homologs revealed
seven conserved residues (R54, F58, D75, D78, R99,
E132 and R135) that are likely important in the protein’s
function. Cross-referencing of these residues with the
observations reported by Gould et al. [31] for the LasI
crystal structure revealed that these residues are known
to be crucial for the functionality of LasI. These equiva-
lent residues in LasI were deemed to be essential for
AHL synthesis and contribute towards the stability of
intra-structural interactions with possible catalytic
functions. Additionally, the equivalent residue for E101
(corresponding to E132 in BPSL1375) is bound to two
commonly conserved water molecules in AHL synthase
that is known to partake in the enzyme’s catalytic
mechanism [31].
Fig. 5 Hemolytic activity of the wild type and mutant proteins. The hemolytic activity was carried out on 1 % rabbit erythrocyte solution at
different temperatures a and at different erythrocyte concentrations ranging from 0.2 to 2.5 % b after 60 min incubation at 37 °C. ‘B. pseudomallei’
refers to B. pseudomallei lysate;‘BPSL175’ refers to the recombinant protein; mutants are denoted by the scheme “m_Original residue_Residue
number_Substituted residue”; PBS refers to phosphate buffered saline
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Based on our modeling of the LasI structure (PDB ID:
1RO5), the most suitable amino acid substitutions that
preserved the function of the conserved residues were
R54K, F58W, D75E, D78E, R99K, E132D and R135K.
These substitute amino acids were selected because they
can maintain a similar 3D space and amino acid se-
quence characteristic to that of the wild type protein.
The substitution of R with K and D with E were carried
out to minimize the disturbance of protein fold and
structural characteristics, either locally or globally. In
this study, the substituted residues were visually scruti-
nized using Chimera to show the reduction and addition
of hydrogen bonds that resulted from the changes, sug-
gesting that the resulting mutants of these residues may
show different levels of hemolytic activity.
Consequently, site directed mutagenesis of these seven
conserved residues resulted in six successful substitu-
tions and each mutant displayed different degrees of
hemolytic capacity. The mutants R99K and R135K
showed a complete loss of hemolytic activity and inter-
estingly the D78E mutant showed a significant 2.3 fold
increase in hemolytic activity. Although the exact mo-
lecular mechanisms for the hemolysis we observed is
not yet known, the differences between the degree of
hemolysis for each mutant can provide important clues
with regards to the contribution of these residues in mo-
lecular interactions that result in hemolytic activity. The
complete loss of hemolytic activity for mutants of R99
and R135 highlighted that these residues must play a
crucial role in the activity of BPSL1375.
Our investigations into the hemolytic activity of
BPSL1375 and the six mutants on different erythrocyte
concentrations revealed that hemolytic activity decreased
with an increase in the ratio between the protein mol-
ecule and erythrocyte thus implying that one erythrocyte
required a certain number of ‘hits’ by the protein to in-
duce lysis, a mechanism known as ‘multi-hits’. This
mechanism has also been observed in Synechocystic sp.
hemolysin, a cyanobacterial toxin [37].
Conclusions
In this study, a B. pseudomallei open reading frame
identified using the BpK96243 genome sequence [27]
that was initially annotated to encode a hypothetical
protein, was characterized as an N-acyltransferase that
exhibits hemolytic activity. Genetic manipulation of the
residues associated with N-acyltransferase activity re-
sulted in marked detectable variations of hemolytic ac-
tivity. Although the exact mechanism that resulted in
the differences in the exhibited hemolytic activity could
not be pinpointed, this study demonstrated the highly
useful utility that modeling of amino acid substitutions
of available well characterized high resolution structures
in the PDB can be reliably transferred to a homolog with
very low sequence similarity and thus enabling func-
tional characterization of the remote homolog. Based on
our results, R99 and R135 are most likely crucial for
function due to the complete loss of activity resulting
from their substitution and therefore likely to be among
the most highly conserved residues for this family of
hemolytic N-acyltansferase (COG3176 family). Our work
also demonstrated that BPSL1375 and the mutants pos-
sess a multi-hit hemolytic activity towards erythrocytes




Sequence homologs of BPSL1375 were retrieved using
BLASTP searches (http://blast.ncbi.nlm.nih.gov) against
the following databases: GenBank refseq, SWISSPROT/
UniProt [29], Protein Data Bank (PDB) [30] and the
Burkholderia Genome Database [39]. Multiple sequence
alignments were performed with ClustalW [40].
Protein structure modeling and analysis
Models were visualized and analyzed using Chimera
[33]. Modeling of mutations, structure comparisons and
model refinements were also carried out using Chimera
Strains, vectors, enzymes and chemicals
B. pseudomallei strain D286 was previously isolated
from a fatal melioidosis case at Kuala Lumpur Hospital
[41]. A stock culture of this strain was obtained from
the Pathogen Laboratory, Faculty of Science and
Technology, Universiti Kebangsaan Malaysia. E. coli
BL21(DE3) and pET200/D-TOPO were obtained from
Invitrogen, USA and other kits as well as reagents were
obtained from standard commercial resources.
Primer design
The ORFs for B. pseudomallei K96243 were generated
using ARTEMIS 13.0. Corresponding primers were then
designed for the ORF identified as bpsl1375 (Table 1).
An additional CACC sequence (5’-CACCATGCGA-
GAACTGCCGA-3’) was added to the 5’- end to allow
direct cloning into the expression vector. The primers
(Table 1) for Quik-Change site directed mutagenesis
were designed using a program provided by Stratagene.
Genomic DNA preparation
B. pseudomallei D286 was plated on Ashdown selective
agar plates. A single colony was inoculated into Brain
Heart Infusion broth (Pronadisa, Spain) and grown over-
night at 37 °C; the bacterial cells were harvested and the
cell pellet was dissolved in TE buffer (10 mM Tris–HCl,
1 mM EDTA, pH 7.5). The pellet was treated with Pro-
teinase K (20 mg/ml) and incubated at 37 °C for 1 h.
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CTAB-NaCl (5 M NaCl) (Sigma, USA) was added and
the incubation was continued at 65 °C for 20 min. B.
pseudomallei genomic DNA extraction was carried out
according to standard protocols as described by Richards
et al. [42]. Purification of genomic DNA was carried out
according to the standard phenol chloroform method
and precipitated using 0.6 volume of isopropanol.
Amplification and cloning of bpsl1375
DNA amplification by polymerase chain reaction (PCR)
was carried out in a final volume of 50 μl containing 10
X Expand High Fidelity buffer with 15 mM MgCl2
(Sigma Chemical, USA), 10 mM dNTP (Sigma Chemical,
USA), 200 ng/μl B. pseudomallei genome, 25 μM for-
ward and reverse primers, 3.5 U/μl High Fidelity Taq
polymerase (Roche, German) and ddH2O. The amplifica-
tion was performed over 30 cycles of denaturation at
94 °C for 1 min, annealing at 67 °C for 1 min and elong-
ation at 72 °C for 1 min. A final extension step was car-
ried out for 10 min at 72 °C. The amplified products
were cloned into pET200/D-TOPO according to the
manufacturer’s recommendation (Invitrogen, USA). The
gene orientation and sequence fidelity were verified by
Sanger DNA sequencing.
Construction of mutants
Single residue mutations were produced using the
Stratagene QuikChange site-directed mutagenesis kit.
The wild type pET200-bpsl1375 construct was used as a
DNA template. The mutations were confirmed by auto-
mated DNA sequencing. Six mutants were produced:
R54K, D75E, D78E, R99K, E132D and R135K.
Expression and purification of BPSL1375 and its related
mutants
Recombinant bpsl1375 and the corresponding mutants
were transformed into E. coli BL21 Star (DE3) according
to the kit manufacturer’s recommendations (Invitrogen,
USA). The bacterial cells were grown on LB (Pronadisa,
Spain)-Kanamycin (30 μg/ml) agar plates for 16 h at 37 °
C. A single colony was inoculated into 5 ml LB-
Kanamycin (30 μg/ml) and incubated at 30 °C overnight
with shaking at 250 rpm. The overnight culture was sub-
cultured into 50 ml of LB-Kanamycin (30 μg/ml) and
grown at 30 °C with shaking at 250 rpm. At OD600 = 0.5,
expression was induced with 1 mM IPTG (Promega,
USA) for 6 h at 30 °C. Cells were harvested and protein
extraction procedures were performed at 4 °C. The cell
pellet was resuspended in 1 mL PBS buffer, sonicated for
10 s at 50 Hz and then centrifuged at 3200 g for 30 min.
The supernatant containing soluble protein was col-
lected and stored at −20 °C. His-tagged protein purifica-
tion was performed using a HisTrap TM HP column (GE
Healthcare). The column was washed with wash buffer
(50 mM NaH2PO4, 300 mM NaCl, 50 mM imidazole,
pH 7.4) and eluted with elution buffer (50 mM
NaH2PO4, 300 mM NaCl, 300 mM imidazole, pH 7.4).
The eluted protein fractions were concentrated using
Vivaspin 6 (MW 10 kDa) (Vivascience, Germany). Pro-
tein concentration was determined using the bicinchoni-
nic acid method (Sigma Chemical, USA) and analyzed
by 12 % SDS-PAGE electrophoresis followed by Western
immunoblotting with anti-mouse IgG conjugated with
HRP (Invitrogen, USA). C
Ethics statement and consent
Blood samples from rabbit and sheep were generously
provided by the Animal House Facility, Universiti
Kebangsaan Malaysia (UKM). Blood was drawn in ac-
cordance with the UKM animal ethics guideline formu-
lated based on the guidelines of the National Health and
Medical Research Council of Australia. The experiments
were approved by the UKM Animal Ethics Committee
(UKMAEC) under approval number FST/SBB/2010/
SHEILA/24-AUGUST/320. All animals were maintained
in a positive pressure environment at 20–25 °C, sub-
jected to a 12 h light/dark cycle and fed with a protein-
enriched diet and water ad libitum. No human subjects
were used in the experiments reported in this paper.
Preparation of rabbit erythrocyte suspensions
Rabbit whole blood in anticoagulant citrate dextrose was
centrifuged at 750 g for 10 min. Plasma and white blood
cells were discarded by removing the supernatant. Eryth-
rocytes were washed with PBS three times following
centrifugation at 750 g for 10 min.
Measurement of hemolytic activity
Rabbit erythrocyte suspensions were adjusted to 4 %
with PBS. The purified proteins and B. pseudomallei ly-
sates were adjusted to 10 μg/ml. Then, 0.1 ml of this so-
lution was incubated with 0.1 ml of 4 % erythrocyte
suspension at 37 °C for 1 h. The samples were centri-
fuged at 750 g for 5 min to remove undamaged erythro-
cytes. The concentration of released hemoglobin was
estimated by reading the absorbance at 545 nm against
the control background lysis solution (erythrocyte suspen-
sion with PBS) using the Ultraspec 2100 pro (Amersham
Biosciences). The percentage of hemolysis was calculated
by normalizing against the absorbance of a mixture of
erythrocytes and distilled water at the same ratio, which
showed complete hemolysis.
To determine the effect of hemolytic activity on differ-
ent amounts of red blood cells, rabbit erythrocyte sus-
pensions at different concentrations (0.2 %, 0.4 %, 0.6 %,
0.8 %, 1.0 %, 1.5 %, 2.0 % and 2.5 %) in PBS were used.
These diluted cell suspensions were incubated with an
equal volume (1.0 μg) of B. pseudomallei lysate, purified
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BPSL1375 or the mutant protein for 1 h at 37 °C and
then centrifuged at 750 g for 5 min to determine the
hemolytic activity. For temperature-dependent studies,
equal volumes (1.0 μg) of B. pseudomallei lysate, purified
BPSL1375 and the mutant proteins were incubated with
1 % rabbit erythrocytes at 4 °C, 20 °C and 37 °C for 1 h
and 60 °C for 15 min. The mixtures were centrifuged at
750 g for 5 min and the residual hemolytic activity of the
supernatant was determined.
Scanning electron microscopy
Sheep erythrocytes (5 %) incubated with BPSL1375 were
fixed in 2 % (v/v) glutaraldehyde, 0.1 M PBS (pH 7.4) over-
night. Prior to dehydration in ethanol, samples were
washed in PBS three times for 10 min. Critical point dry-
ing was performed with acetone and sputter-coated with
gold-palladium. The samples were observed with a Philips
XL30 scanning electron microscope at the Universiti
Kebangsaan Malaysia Electron Microscopy Facility.
Additional file
Additional file 1: Figure A and B. SDS PAGE (A) of soluble fractions for
wild type recombinant BPSL1375, R54K mutant, D75E mutant and the
corresponding Western blot (B). Lane 1: Broad range marker; Lane 2: E.
coli BL21 (DE3) StarTM - IPTG; Lane 3: E. coli BL21 (DE3) StarTM + IPTG;
Lane 4: BPSL1375 – IPTG; Lane 5: BPSL1375 + IPTG; Lane 6: R54K – IPTG;
Lane 7: R54K + IPTG; Lane 8: D75E – IPTG; Lane 9: D75E + IPTG; Lane 10:
purified BPSL1375. Figure C and D. SDS PAGE (C) of soluble fractions for
wild type recombinant BPSL1375, D78E mutant, R99K mutant and the
corresponding Western blot (D). Lane 1: Broad range marker; Lane 2: E.
coli BL21 (DE3) StarTM - IPTG; Lane 3: E. coli BL21 (DE3) StarTM + IPTG;
Lane 4: BPSL1375 – IPTG; Lane 5: BPSL1375 + IPTG; Lane 6: D78E – IPTG;
Lane 7: D78E + IPTG; Lane 8: R99K – IPTG; Lane 9: R99K + IPTG; Lane 10:
purified BPSL1375. Figure E and F. SDS PAGE (E) of soluble fractions for
wild type recombinant BPSL1375, E132D mutant, R135K mutant and the
corresponding Western blot (F). Lane 1: Broad range marker; Lane 2: E.
coli BL21 (DE3) StarTM - IPTG; Lane 3: E. coli BL21 (DE3) StarTM + IPTG;
Lane 4: BPSL1375 – IPTG; Lane 5: BPSL1375 + IPTG; Lane 6: E132D – IPTG;
Lane 7: E132D + IPTG; Lane 8: R135K – IPTG; Lane 9: R135K + IPTG; Lane
10: purified BPSL1375. (PDF 469 kb)
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